InvestorsHub Logo
Followers 20
Posts 5332
Boards Moderated 0
Alias Born 01/04/2012

Re: Just the facts maam post# 6202

Saturday, 01/07/2017 1:43:35 PM

Saturday, January 07, 2017 1:43:35 PM

Post# of 14872
The CEO of ENDO, Paul V. Campanelli, is the former CEO of PAR Pharmaceuticals.

In the last quarterly filing he was asked if Endo was going to enter the biosimilar market. Campanelli did not want to get deep into their strategy bu that they are focusing on polypetides.

ENDO Q3 trnascript

Could the Molecular Biologist position in Irvine California be related to a Biosimilar development partnership with ENDO?

Something to keep an eye out for.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News